The chemicals giant known for fertilizers and plastics is taking on one of the world’s most valuable technology companies in a Texas courtroom. BASF has filed suit against Apple, alleging that the Cupertino-based group’s Face ID and face-authentication features in iPhones and iPads infringe on patents held by the Ludwigshafen group. The company is seeking both damages and an injunction, though it has not disclosed the specific sum it is pursuing or the precise value it attaches to the disputed intellectual property.
For a group whose identity has long been tied to chemicals, polymers and agricultural products, the legal offensive marks an unusual foray into the cut-and-thrust of consumer-technology litigation. It also throws a spotlight on a side of BASF that equity investors rarely pause to consider: a patent portfolio in facial-recognition technology that management is evidently prepared to defend in court.
The Capital-Returns Engine Keeps Turning
The Apple dispute may be generating headlines, but the machinery of shareholder returns is operating on a separate track with its own momentum. BASF continued its share repurchase programme through late August, buying 591,251 of its own shares in the week of 24-28 August, following 557,966 the week before. Those purchases fall under the new buyback envelope of up to €1.0 billion approved at the end of July, which began in August and runs until the end of April 2027.
The current programme is the latest instalment of a longer capital strategy. Between November 2025 and June 2026, BASF repurchased shares worth €1.5 billion and earmarked roughly 31.6 million securities — equivalent to 3.5 per cent of share capital — for cancellation. Management’s ambitions stretch further still: a total of €4 billion in buybacks through 2028, layered on top of dividend payments of around €8 billion, implying shareholder distributions of at least €12 billion across the 2025-2028 window.
Balance-sheet repair runs in parallel. The group plans early repayment of bonds and loans with a nominal volume of €1.6 billion in the third quarter, a deleveraging step eased by the roughly €5.8 billion pre-tax proceeds from the Coatings disposal to Carlyle that closed in June. That combination of buybacks, dividends and debt reduction is intended to signal that the upgraded full-year guidance — EBITDA before special items now seen between €6.9 billion and €7.7 billion — rests on solid operational foundations.
Operational Cadence Continues Uninterrupted
While lawyers prepare for a lengthy fight in Texas, the operational calendar has not paused. At the Ludwigshafen Verbund site, BASF has formally commissioned a modernised plant for acid chlorides and chloroformates, expanding capacity for specialty chemicals at its flagship location. The group has also taken home the Ringier Technology Innovation Award in the Functional Chemicals category for its Plantapon Amino ASP product — an accolade that may move few spreadsheets but underscores the steady innovation pipeline in specialty chemistry.
Should investors sell immediately? Or is it worth buying BASF?
Pricing power has been exercised across several product lines, with increases implemented for caprolactam and nylon precursors in North America, alongside neopentyl glycol and 1,6-hexanediol in both Europe and North America. Such adjustments are routine in the chemicals trade, serving chiefly to offset rising raw-material and energy costs.
Geographic Expansion and the Asian Growth Bet
Beyond the balance-sheet mechanics, BASF continues to place strategic chips on Asian growth markets. On 18 August, the group inaugurated a new performance lab for superabsorbents in Mumbai — materials used in products such as nappies — offering technical services to customers on a global basis and underscoring India’s rising importance to the hygiene business. That facility is modest next to the Verbund site in Zhanjiang, China, which was completed earlier in the year: roughly €8.7 billion bought 18 production units and 32 production lines turning out more than 70 products, delivered on schedule and within budget.
Where the Share Price Sits
The stock has been trading in the upper reaches of its recent range. One source puts the latest quote at €53.19, another at €52.94 — in either case within a few percentage points of the 52-week high of €55.05 marked in April, and comfortably above the 200-day average of €48.89. The distance to the 52-week low of €41.55 is a chunky 27 per cent, suggesting the market has been rewarding the group’s strategic progress. The next scheduled catalyst is the quarterly earnings release on 28 October, which will offer a fresh read on pricing trends in specialty chemicals and the pace of the Ludwigshafen ramp-up.
As for the Apple litigation, investors would be wise not to hold their breath: patent disputes of this kind routinely drag on for years, and the outcome is unlikely to move the share price meaningfully in the near term. The more immediate drivers remain the buyback cadence, the deleveraging trajectory and the operational execution visible in the numbers.
Ad
BASF Stock: Buy or Sell?! New BASF Analysis from September 4 delivers the answer:
The latest BASF figures speak for themselves: Urgent action needed for BASF investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 4.
BASF: Buy or sell? Read more here...
